A share price of BioAtla Inc [BCAB] is currently trading at $2.84, up 14.98%. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The BCAB shares have gain 17.84% over the last week, with a monthly amount glided 37.86%, and seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
On 20, December 2023, BioAtla to Participate in the 42nd Annual J.P. Morgan Healthcare Conference. In a post published today on Yahoo Finance, BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today announced that the Company’s management will participate in a fireside chat and one-on-one investor meetings at the 42nd Annual J.P. Morgan Healthcare Conference, to be held in San Francisco, CA January 8-11, 2024.
From an analyst’s perspective:
BioAtla Inc [NASDAQ: BCAB] stock has seen the most recent analyst activity on September 15, 2022, when JMP Securities initiated its Mkt Outperform rating and assigned the stock a price target of $17. Previously, Credit Suisse downgraded its rating to Neutral on May 05, 2022, and dropped its price target to $5. On March 21, 2022, H.C. Wainwright initiated with a Buy rating and assigned a price target of $25 on the stock. ROTH Capital initiated its recommendation with a Buy and recommended $75 as its price target on June 28, 2021.
BioAtla Inc experienced fluctuations in its stock price throughout the past year between $1.24 and $4.07. BioAtla Inc [NASDAQ: BCAB] shares were valued at $2.84 at the most recent close of the market.
Analyzing the BCAB fundamentals
Gross Profit Margin for this corporation currently stands at -0.03% with Operating Profit Margin at -0.22%, Pretax Profit Margin comes in at -0.24%, and Net Profit Margin reading is -0.51%. To continue investigating profitability, this company’s Return on Assets is posted at -1.53, Equity is -2.61 and Total Capital is -22.65. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of-6.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 2.57 points at the first support level, and at 2.31 for the second support level. However, for the 1st resistance point, the stock is sitting at 2.98, and for the 2nd resistance point, it is at 3.12.
BioAtla Inc [BCAB] reported earnings per share of -$0.7 for its fiscal quarter that ended on 9/29/2023. Based on the Wall Street analysts’ estimates, the company was expected to report earnings of -$0.8/share, meaning a difference of $0.1 and a surprise factor of 12.50%. By comparison, the stated earnings for the previous quarter ended on 6/29/2023 were -$0.75 per share as compared to estimates of -$0.64 per share, a difference of -$0.11 representing a surprise of -17.20%.
Ratios To Look Out For
To put it in perspective, the Current Ratio for BioAtla Inc [NASDAQ:BCAB] is 4.14. As well, the Quick Ratio is 4.14, while the Cash Ratio is 0.05.
Transactions by insiders
Insider trading has also been a hot topic recently, with 1 insiders purchasing 4,000 shares and 0 selling 0 shares in the past 3 months. Recent insider trading involved MCBRINN SYLVIA, Director, that happened on Dec 26 when 4000.0 shares were purchased. Chief Executive Officer, SHORT JAY M PHD completed a deal on Dec 20 to buy 50000.0 shares. Meanwhile, Director STEINMAN LAWRENCE bought 20000.0 shares on Dec 19.
